Hertz Laura, Huisjes Rick, Llaudet-Planas Esther, Petkova-Kirova Polina, Makhro Asya, Danielczok Jens G, Egee Stephane, Del Mar Mañú-Pereira Maria, van Wijk Richard, Vives Corrons Joan-Lluis, Bogdanova Anna, Kaestner Lars
Research Centre for Molecular Imaging and Screening, Medical School, Saarland UniversityHomburg, Germany.
Department of Clinical Chemistry and Haematology, University Medical Center UtrechtUtrecht, Netherlands.
Front Physiol. 2017 Sep 6;8:673. doi: 10.3389/fphys.2017.00673. eCollection 2017.
For many hereditary disorders, although the underlying genetic mutation may be known, the molecular mechanism leading to hemolytic anemia is still unclear and needs further investigation. Previous studies revealed an increased intracellular Ca in red blood cells (RBCs) from patients with sickle cell disease, thalassemia, or Gardos channelopathy. Therefore we analyzed RBCs' Ca content from 35 patients with different types of anemia (16 patients with hereditary spherocytosis, 11 patients with hereditary xerocytosis, 5 patients with enzymopathies, and 3 patients with hemolytic anemia of unknown cause). Intracellular Ca in RBCs was measured by fluorescence microscopy using the fluorescent Ca indicator Fluo-4 and subsequent single cell analysis. We found that in RBCs from patients with hereditary spherocytosis and hereditary xerocytosis the intracellular Ca levels were significantly increased compared to healthy control samples. For enzymopathies and hemolytic anemia of unknown cause the intracellular Ca levels in RBCs were not significantly different. These results lead us to the hypothesis that increased Ca levels in RBCs are a shared component in the mechanism causing an accelerated clearance of RBCs from the blood stream in channelopathies such as hereditary xerocytosis and in diseases involving defects of cytoskeletal components like hereditary spherocytosis. Future drug developments should benefit from targeting Ca entry mediating molecular players leading to better therapies for patients.
对于许多遗传性疾病,尽管潜在的基因突变可能已知,但导致溶血性贫血的分子机制仍不清楚,需要进一步研究。先前的研究表明,镰状细胞病、地中海贫血或加尔多斯通道病患者的红细胞(RBC)内的钙离子增加。因此,我们分析了35例不同类型贫血患者的红细胞钙离子含量(16例遗传性球形红细胞增多症患者、11例遗传性口形红细胞增多症患者、5例酶病患者和3例病因不明的溶血性贫血患者)。使用荧光钙指示剂Fluo-4通过荧光显微镜和随后的单细胞分析测量红细胞内的钙离子。我们发现,与健康对照样本相比,遗传性球形红细胞增多症和遗传性口形红细胞增多症患者的红细胞内钙离子水平显著升高。对于酶病和病因不明的溶血性贫血,红细胞内钙离子水平无显著差异。这些结果使我们提出一个假设,即红细胞内钙离子水平升高是导致遗传性口形红细胞增多症等通道病以及遗传性球形红细胞增多症等涉及细胞骨架成分缺陷的疾病中红细胞从血流中加速清除机制的一个共同组成部分。未来的药物开发应受益于针对介导钙离子进入的分子靶点,从而为患者带来更好的治疗方法。